Black Diamond Therapeutics, INC

Black Diamond Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Black Diamond Therapeutics announced positive Phase 2 results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, showing a 15.2-month median progression-free survival.

Black Diamond Therapeutics reported Q1 2026 financial results, highlighting $118.3 million in cash and providing updates on its silevertinib clinical trials.

Black Diamond Therapeutics reported strong financial results for Q4 and full year 2025, driven by operational efficiencies and a significant increase in cash, alongside positive clinical updates for silevertinib.

Black Diamond Therapeutics announced positive preliminary Phase 2 data for silevertinib in 1L NSCLC and plans for a new Phase 2 trial in GBM, extending its cash runway into late 2028.

Black Diamond Therapeutics reported improved Q3 2025 financial results and anticipates key clinical data for silevertinib in non-classical EGFRm NSCLC this quarter.

Black Diamond Therapeutics reports a net loss of $9.0 million for Q1 2026, with cash reserves projected to fund operations into the second half of 2028.

Black Diamond Therapeutics reported a net income of $37.5 million for the nine months ended September 30, 2025, driven by a $70 million upfront payment from its global licensing agreement with Servier for BDTX-4933, while continuing to advance its lead oncology candidate, silevertinib.

Black Diamond Therapeutics reported a significant financial turnaround in Q2 2025, driven by a $70 million licensing deal and operational efficiencies, extending its cash runway into Q4 2027.

Black Diamond Therapeutics posts a profitable first quarter in 2025, driven by a significant licensing agreement with Servier for BDTX-4933.

Black Diamond Therapeutics reported its Q3 2024 financial results and announced a corporate restructuring to prioritize its lead program, BDTX-1535.

Black Diamond Therapeutics reports a net loss of $19.9 million for the second quarter of 2024, while advancing its clinical programs for BDTX-1535 and BDTX-4933.

Black Diamond Therapeutics focuses on advancing BDTX-1535, a brain-penetrant EGFR MasterKey inhibitor, after reporting its 2024 financial results and implementing a corporate restructuring.

Black Diamond Therapeutics' 10-K filing details the company's common and preferred stock structure, anti-takeover measures, and corporate governance policies.

Director Ali Behbahani of Black Diamond Therapeutics, Inc. acquired stock options for 40,000 shares, with vesting contingent on continued service.

Director Samarth Kulkarni of Black Diamond Therapeutics, Inc. acquired 40,000 stock options with an exercise price of $1.71.

Garry E. Menzel, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Raman Prakash, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026, with an exercise price of $1.71.

Kapil Dhingra, a Director at Black Diamond Therapeutics, acquired 40,000 stock options with an exercise price of $1.71.

Shannon Campbell, a Director at Black Diamond Therapeutics, Inc., acquired 40,000 stock options on June 26, 2026.

Black Diamond Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 26, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 12, 2025.

Black Diamond Therapeutics will hold its 2025 Annual Meeting of Stockholders online on June 12, 2025, to elect directors and ratify the appointment of its accounting firm.

Black Diamond Therapeutics will hold its annual stockholders meeting virtually on June 6, 2024, to vote on key proposals including the election of directors and ratification of the company's accounting firm.

Black Diamond Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, to vote on director elections, auditor ratification, and an amendment to limit officer liability.

T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 7.0% of Black Diamond Therapeutics' common stock as of June 30, 2026.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Black Diamond Therapeutics, Inc. as of March 31, 2025, indicating a reduction from a previously reportable position.

BB Biotech AG and its wholly-owned subsidiary, Biotech Growth N.V., have reported a 4.8% beneficial ownership stake in Black Diamond Therapeutics, Inc. as of March 19, 2025.

BB Biotech AG and its wholly-owned subsidiary, Biotech Growth N.V., have disclosed a combined beneficial ownership of 15.1% in Black Diamond Therapeutics, Inc., holding 8,517,839 shares of common stock as of December 31, 2024.